Tomas Leanderson (Former)
11 – 20 of 84
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis.
(
- Contribution to journal › Article
-
Mark
Myeloid-related protein 14 promote inflammation and injury in meningitis.
(
- Contribution to journal › Article
-
Mark
S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
(
- Contribution to journal › Article
- 2014
-
Mark
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
(
- Contribution to journal › Article
-
Mark
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
(
- Contribution to journal › Article
-
Mark
The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects.
(
- Contribution to journal › Article
-
Mark
Quinoline-3-carboxamides modulate primary T cell-dependent B cell responses but do not inhibit functional immunity.
(
- Contribution to journal › Article
- 2013
-
Mark
Common Interactions between S100A4 and S100A9 Defined by a Novel Chemical Probe.
(
- Contribution to journal › Article
-
Mark
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
(
- Contribution to journal › Article
-
Mark
Mice Lacking NCF1 Exhibit Reduced Growth of Implanted Melanoma and Carcinoma Tumors.
(
- Contribution to journal › Article